Tara Petersen

During the past several years, a wealth of positive clinical trials coupled with an evolution in understanding of neuroendocrine tumors has altered the treatment landscape.

The antibody–drug conjugate sacituzumab govitecan (IMMU-132) received a breakthrough therapy designation based on phase II trial data showing a response rate of 31% in heavily pretreated patients with metastatic TNBC. However, treatment advances are lagging behind those seen in other breast cancer phenotypes.

Questions remain in terms of how to optimally sequence and/or combine both targeted agents and immunotherapies in melanoma.

With scores of subtypes and a paucity of molecular markers, soft tissue sarcoma remains a complex and challenging tumor type to treat yet significant strides being made in the field are likely to alter the therapeutic paradigm.

As new targeted and immunologic agents are introduced for patients with lung cancer, clinicians have more factors to consider than ever before when developing treatment plans for their patients.

Recent evidence has shed some light on the prognostic value of microsatellite instability and the potential benefit of checkpoint inhibition in colorectal cancer.

Although guideline organizations have now incorporated the results of major clinical trials into treatment paradigms, much controversy remains over how best to sequence therapies in prostate cancer.